BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 9, 2005
View Archived Issues
Money Raised Year To Date
Read More
Stock Winners and Losers For The Week
Read More
Public Financing Of Biotechnology: April 2005
Read More
Other Financings Of Public Biotechnology Companies: April 2005
Read More
Venture Capital And Corporate Investments In Biotechnology Companies: April 2005
Read More
Tysabri Slump Creates Buying Edge For Long-Term Investors
When Amylin Pharmaceuticals Inc. won approval of its second diabetes drug in as many months, Byetta (exenatide), the company's stock - rather than skyrocketing, as likely would have happened in the old days - fell 6 percent.
Read More
Money Raised By Month
Read More
Stock Indexes
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More